VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)

News

Editas Medicine GAAP EPS of -$0.76 misses by $0.18, revenue of $1.14M misses by $6.16M [Seeking Alpha]
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Royal Bank of Canada from $417.00 to $424.00. They now have a "sector perform" rating on the stock.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Piper Sandler from $450.00 to $456.00. They now have an "overweight" rating on the stock.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com